Onconetix signs LOI for business combination with Ocuvex; Ocuvex holders to own ~90%

Onconetix, Inc.

Non-binding LOI with Ocuvex Therapeutics, a private ophthalmic biopharma company with FDA-approved product and late-stage clinical assets.
Upon closing, Onconetix will issue new shares to acquire all Ocuvex equity; Ocuvex holders to own ~90% of combined company.
Transaction subject to due diligence, definitive agreement, financing, regulatory and stockholder approvals; no assurance of completion.
Onconetix Chairman Andrew J. Oakley states combination will 'immediately expand our reach beyond oncology, enhancing shareholder value.'
Ocuvex President/CEO Anthony W. Amato notes combining will 'broaden access to capital.'

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.